ALAMAST
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Sep 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALAMAST is an ophthalmic solution approved in 1999 for allergic conjunctivitis and related eye conditions. The drug is a small-molecule mast cell stabilizer delivered as eye drops. It functions by preventing mast cell degranulation to reduce allergic inflammatory responses in the eye.
LOE Approaching
Product is in decline phase with 30% competitive pressure, indicating a contracting team focused on maintenance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ALAMAST offers 64 linked career opportunities, primarily in Commercial and Medical Affairs roles with strong geographic focus on Asia-Pacific markets managed by sponsor Santen. This LOE-approaching product prioritizes safety vigilance, technical expertise, and regional sales management over innovation roles.
[Singapore] Global Safety Vigilance Risk Management Lead
Worked on ALAMAST at Santen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.